Kare Schultz - 01 Nov 2022 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Reporting relationship: President and CEO, Director
Issuer ticker: TEVA
Reported as of: 01 Nov 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Nov 2022, 08:55:01 UTC
Prior SEC filing: 06 May 2022
Next SEC filing: 22 Jul 2024
Source filing: View source filing
Reporting owner signature: /s/ Dov Bergwerk as attorney-in-fact for Kare Schultz

Key filing fact

Kare Schultz filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 02 Nov 2022.

Key facts

This page summarizes Kare Schultz's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 02 Nov 2022, 08:55.

Change

Previous filing in this sequence was filed on 06 May 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TEVA transaction

Ordinary Shares

Options Exercise

Transaction value
Shares: +116,389
Change %: +8.2%
Price
Shares after: 1,542,471
Date: 01 Nov 2022
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TEVA transaction Derivative

Restricted Share Units

Options Exercise

Transaction value: $0
Shares: -116,389
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 01 Nov 2022
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 116,389
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Footnote F2

Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

Footnote F3

Restricted share units were granted on November 3, 2017 with 63,613 vested on November 3, 2019, 180,000 vested on each of November 1, 2020 and November 1, 2021 and 116,389 vested on November 1, 2022.